Name of the medicinal product: BUATERON

Content: Each vial contains 19,1mg Calcium folinate equivalent to 15mg folinic acid.

Pharmaceutical form: Powder and liquid solution for a single oral dose

Pharmacotherapeutic group: BUATERON acts against the toxicity of folic acid antagonists

Packaging description: The inner container consists of a glass vial containing the liquid solution of the excepients and the cap – pock, which contains the mixture of powders (active ingredient and excipient) and small plastic plunger to propel the powder mixture in the solution. The pock is covered by a special cap. Ten glass vials packed in a cardboard box together with the operating instructions.

BUATERON can reduce the toxic effects of anticancer drugs that are antagonists of folic acid such as of methotrexate.
Rescue therapy, following the administration of high-dose methotrexate, in cases such as osteosarcoma. Dealing with toxicity from delayed excretion of methotrexate or excessive intake of folic acid antagonists such as pyrimethamine and trimethoprim.
Treatment of megaloblastic anemia due to lack of folic acid.
BUATERON is not indicated in pernicious anemia and other megaloblastic anemias, caused by lack of vitamin B12 or are of unknown etiology. There may be blood recession, but the neurological manifestations will continue to evolve. It should not be administered to anemia of tumors, because it can favor the development of anxiety.
BUATERON be taken orally. Because saturation in absorbing, can return, the oral doses should not exceed 25mg.